Advertisement
Singapore markets closed

  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     

  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • FTSE 100

    8,437.67
    +56.32 (+0.67%)
     

  • Bitcoin USD

    62,264.37
    +967.55 (+1.58%)
     

  • CMC Crypto 200

    1,295.27
    -62.74 (-4.62%)
     

  • S&P 500

    5,220.00
    +5.92 (+0.11%)
     

  • Dow

    39,518.09
    +130.33 (+0.33%)
     

  • Nasdaq

    16,331.07
    -15.20 (-0.09%)
     

  • Gold

    2,369.60
    +29.30 (+1.25%)
     

  • Crude Oil

    79.37
    +0.11 (+0.14%)
     

  • 10-Yr Bond

    4.4920
    +0.0430 (+0.97%)
     

  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     

  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     

  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment

Reuters
Updated

(Reuters) - AstraZeneca Plc <AZN.L> and Merck & Co Inc <MRK.N> said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo.

Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.

(The story corrects typo in the first paragraph.)

(Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)